{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:02:30Z","timestamp":1780981350673,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National cancer institute","award":["R01CA223767"],"award-info":[{"award-number":["R01CA223767"]}]},{"name":"National Cancer Institute","award":["CCSG P30 CA44579"],"award-info":[{"award-number":["CCSG P30 CA44579"]}]},{"name":"National Institute of Health","award":["S10OD021672"],"award-info":[{"award-number":["S10OD021672"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We recently identified CD46 as a novel prostate cancer cell surface antigen that shows lineage independent expression in both adenocarcinoma and small cell neuroendocrine subtypes of metastatic castration resistant prostate cancer (mCRPC), discovered an internalizing human monoclonal antibody YS5 that binds to a tumor selective CD46 epitope, and developed a microtubule inhibitor-based antibody drug conjugate that is in a multi-center phase I trial for mCRPC (NCT03575819). Here we report the development of a novel CD46-targeted alpha therapy based on YS5. We conjugated <jats:sup>212<\/jats:sup>Pb, an in vivo generator of alpha-emitting <jats:sup>212<\/jats:sup>Bi and <jats:sup>212<\/jats:sup>Po, to YS5 through the chelator TCMC to create the radioimmunoconjugate, <jats:sup>212<\/jats:sup>Pb-TCMC-YS5. We characterized <jats:sup>212<\/jats:sup>Pb-TCMC-YS5 in vitro and established a safe dose in vivo. We next studied therapeutic efficacy of a single dose of <jats:sup>212<\/jats:sup>Pb-TCMC-YS5 using three prostate cancer small animal models: a subcutaneous mCRPC cell line-derived xenograft (CDX) model (subcu-CDX), an orthotopically grafted mCRPC CDX model (ortho-CDX), and a prostate cancer patient-derived xenograft model (PDX). In all three models, a single dose of 0.74\u00a0MBq (20\u00a0\u00b5Ci) <jats:sup>212<\/jats:sup>Pb-TCMC-YS5 was well tolerated and caused potent and sustained inhibition of established tumors, with significant increases of survival in treated animals. A lower dose (0.37\u00a0MBq or 10\u00a0\u00b5Ci <jats:sup>212<\/jats:sup>Pb-TCMC-YS5) was also studied on the PDX model, which also showed a significant effect on tumor growth inhibition and prolongation of animal survival. These results demonstrate that <jats:sup>212<\/jats:sup>Pb-TCMC-YS5 has an excellent therapeutic window in preclinical models including PDXs, opening a direct path for clinical translation of this novel CD46-targeted alpha radioimmunotherapy for mCRPC treatment.\n<\/jats:p>","DOI":"10.1186\/s13046-023-02636-x","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:24:23Z","timestamp":1679862263000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment"],"prefix":"10.1186","volume":"42","author":[{"given":"Jun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Bidlingmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqiu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil P.","family":"Bidkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngho","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Flavell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gioeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dreicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"2636_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discovery. 2020;19:589\u2013608.","journal-title":"Nat Rev Drug Discovery"},{"key":"2636_CR2","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/COC.0000000000000353","volume":"41","author":"RF Meredith","year":"2018","unstructured":"Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD, et al. Safety and Outcome Measures of First-in-Human Intraperitoneal \u03b1 Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. Am J Clin Oncol. 2018;41:716\u201321.","journal-title":"Am J Clin Oncol"},{"key":"2636_CR3","first-page":"12","volume":"29","author":"RF Meredith","year":"2014","unstructured":"Meredith RF, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, et al. Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm. 2014;29:12\u20137.","journal-title":"Cancer Biother Radiopharm"},{"key":"2636_CR4","doi-asserted-by":"crossref","unstructured":"Kasten BB, Oliver PG, Kim H, Fan J, Ferrone S, Zinn KR, et al. (212)Pb-Labeled Antibody 225.28 Targeted to chondroitin sulfate proteoglycan 4 for triple-negative breast cancer therapy in mouse models. Int J Mol Sci. 2018;19:925.","DOI":"10.3390\/ijms19040925"},{"key":"2636_CR5","doi-asserted-by":"publisher","first-page":"e0230526","DOI":"10.1371\/journal.pone.0230526","volume":"15","author":"AF Maaland","year":"2020","unstructured":"Maaland AF, Saidi A, Torgue J, Heyerdahl H, Stallons TAR, Kolstad A, et al. Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin\u2019s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003. PLoS ONE. 2020;15:e0230526.","journal-title":"PLoS ONE"},{"key":"2636_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2967\/jnumed.119.229393","volume":"61","author":"SR Banerjee","year":"2020","unstructured":"Banerjee SR, Minn I, Kumar V, Josefsson A, Lisok A, Brummet M, et al. Preclinical Evaluation of (203\/212)Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer. J Nucl Med. 2020;61:80\u20138.","journal-title":"J Nucl Med"},{"key":"2636_CR7","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/s41416-021-01585-6","volume":"125","author":"S Durand-Panteix","year":"2021","unstructured":"Durand-Panteix S, Monteil J, Sage M, Garot A, Clavel M, Saidi A, et al. Preclinical study of (212)Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma. Br J Cancer. 2021;125:1657\u201365.","journal-title":"Br J Cancer"},{"key":"2636_CR8","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","volume":"63","author":"ES Delpassand","year":"2022","unstructured":"Delpassand ES, Tworowska I, Esfandiari R, Torgue J, Hurt J, Shafie A, et al. Targeted \u03b1-Emitter Therapy with (212)Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial. J Nucl Med. 2022;63:1326\u201333.","journal-title":"J Nucl Med"},{"key":"2636_CR9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/j.semnuclmed.2019.02.008","volume":"49","author":"HJ Wester","year":"2019","unstructured":"Wester HJ, Schottelius M. PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy. Semin Nucl Med. 2019;49:302\u201312.","journal-title":"Semin Nucl Med"},{"key":"2636_CR10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"2636_CR11","doi-asserted-by":"crossref","unstructured":"Rosar F, Krause J, Bartholom\u00e4 M, Maus S, Stemler T, Hierlmeier I, et al. Efficacy and safety of [(225)Ac]Ac-PSMA-617 augmented [(177)Lu]Lu-PSMA-617 radioligand therapy in patients with highly advanced mCRPC with poor prognosis. Pharmaceutics 2021;13:722.","DOI":"10.3390\/pharmaceutics13050722"},{"key":"2636_CR12","doi-asserted-by":"crossref","unstructured":"Stenberg VY, Larsen RH, Ma LW, Peng Q, Juzenas P, Bruland \u00d8 S, et al. Evaluation of the PSMA-Binding Ligand (212)Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer. International journal of molecular sciences 2021;22","DOI":"10.3390\/ijms22094815"},{"key":"2636_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40291-022-00594-2","volume":"26","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Lutetium Lu 177 Vipivotide Tetraxetan: First Approval. Mol Diagn Ther. 2022;26:467\u201375.","journal-title":"Mol Diagn Ther"},{"key":"2636_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.nucmedbio.2021.04.003","volume":"98\u201399","author":"N Heynickx","year":"2021","unstructured":"Heynickx N, Herrmann K, Vermeulen K, Baatout S, Aerts A. The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far. Nucl Med Biol. 2021;98\u201399:30\u20139.","journal-title":"Nucl Med Biol"},{"key":"2636_CR15","doi-asserted-by":"crossref","unstructured":"Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, et al. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight.\u00a02018;3:e121497.","DOI":"10.1172\/jci.insight.121497"},{"key":"2636_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1055\/a-1044-1855","volume":"59","author":"I Alberts","year":"2020","unstructured":"Alberts I, Sachpekidis C, Fech V, Rominger A, Afshar-Oromieh A. PSMA-negative prostate cancer and the continued value of choline-PET\/CT. Nuklearmedizin. 2020;59:33\u20134.","journal-title":"Nuklearmedizin"},{"key":"2636_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12253-008-9104-2","volume":"15","author":"S Mannweiler","year":"2009","unstructured":"Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15:167\u201372.","journal-title":"Pathol Oncol Res"},{"key":"2636_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/978-1-4939-7447-4_18","volume":"1701","author":"Y Su","year":"2018","unstructured":"Su Y, Bidlingmaier S, Lee NK, Liu B. Combine Phage Antibody Display Library Selection on Patient Tissue Specimens with Laser Capture Microdissection to Identify Novel Human Antibodies Targeting Clinically Relevant Tumor Antigens. Methods Mol Biol. 2018;1701:331\u201347.","journal-title":"Methods Mol Biol"},{"key":"2636_CR19","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1074\/mcp.M600246-MCP200","volume":"5","author":"W Ruan","year":"2006","unstructured":"Ruan W, Sassoon A, An F, Simko JP, Liu B. Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection. Mol Cell Proteomics. 2006;5:2364\u201373.","journal-title":"Mol Cell Proteomics"},{"key":"2636_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2967\/jnumed.109.069492","volume":"51","author":"J He","year":"2010","unstructured":"He J, Wang Y, Feng J, Zhu X, Lan X, Iyer AK, et al. Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragment. J Nucl Med. 2010;51:427\u201332.","journal-title":"J Nucl Med"},{"key":"2636_CR21","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1158\/1078-0432.CCR-20-3310","volume":"27","author":"S Wang","year":"2021","unstructured":"Wang S, Li J, Hua J, Su Y, Beckford-Vera DR, Zhao W, et al. Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET. Clin Cancer Res. 2021;27:1305\u201315.","journal-title":"Clin Cancer Res"},{"key":"2636_CR22","doi-asserted-by":"publisher","first-page":"109362","DOI":"10.1016\/j.apradiso.2020.109362","volume":"166","author":"E Napoli","year":"2020","unstructured":"Napoli E, Stenberg VY, Juzeniene A, Hjellum GE, Bruland \u00d8S, Larsen RH. Calibration of sodium iodide detectors and reentrant ionization chambers for (212)Pb activity in different geometries by HPGe activity determined samples. Appl Radiat Isot. 2020;166:109362.","journal-title":"Appl Radiat Isot"},{"key":"2636_CR23","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.nucmedbio.2013.01.010","volume":"40","author":"KE Baidoo","year":"2013","unstructured":"Baidoo KE, Milenic DE, Brechbiel MW. Methodology for labeling proteins and peptides with lead-212 (212Pb). Nucl Med Biol. 2013;40:592\u20139.","journal-title":"Nucl Med Biol"},{"key":"2636_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.apradiso.2017.05.006","volume":"127","author":"M Li","year":"2017","unstructured":"Li M, Zhang X, Quinn TP, Lee D, Liu D, Kunkel F, et al. Automated cassette-based production of high specific activity [(203\/212)Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer. Appl Radiat Isot. 2017;127:52\u201360.","journal-title":"Appl Radiat Isot"},{"key":"2636_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2310\/7290.2010.00046","volume":"10","author":"YY Jang","year":"2011","unstructured":"Jang YY, Ye Z, Cheng L. Molecular imaging and stem cell research. Mol Imaging. 2011;10:111\u201322.","journal-title":"Mol Imaging"},{"key":"2636_CR26","doi-asserted-by":"crossref","unstructured":"McGovern JA, Shafiee A, Wagner F, Lahr CA, Landgraf M, Meinert C, et al. Humanization of the prostate microenvironment reduces homing of pc3 prostate cancer cells to human tissue-engineered bone. Cancers.\u00a02018;10:438.","DOI":"10.3390\/cancers10110438"},{"key":"2636_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/RMR.0000000000000102","volume":"25","author":"JS Burrell","year":"2016","unstructured":"Burrell JS, Walker-Samuel S, Boult JK, Baker LC, Jamin Y, Halliday J, et al. Investigating the Vascular Phenotype of Subcutaneously and Orthotopically Propagated PC3 Prostate Cancer Xenografts Using Combined Carbogen Ultrasmall Superparamagnetic Iron Oxide MRI. Top Magn Reson Imaging. 2016;25:237\u201343.","journal-title":"Top Magn Reson Imaging"},{"key":"2636_CR28","doi-asserted-by":"crossref","unstructured":"Park SI, Kim SJ, McCauley LK, Gallick GE. Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Curr Protoc Pharmacol. 2010;51:14.15.1\u201314.15.27.","DOI":"10.1002\/0471141755.ph1415s51"},{"key":"2636_CR29","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1158\/0008-5472.CAN-17-1958","volume":"78","author":"SK Sharma","year":"2018","unstructured":"Sharma SK, Chow A, Monette S, Vivier D, Pourat J, Edwards KJ, et al. Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models. Can Res. 2018;78:1820\u201332.","journal-title":"Can Res"},{"key":"2636_CR30","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1172\/JCI85856","volume":"126","author":"DW Sherbenou","year":"2016","unstructured":"Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, et al. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Investig. 2016;126:4640\u201353.","journal-title":"J Clin Investig"},{"key":"2636_CR31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.tranon.2017.04.004","volume":"10","author":"DE Milenic","year":"2017","unstructured":"Milenic DE, Baidoo KE, Kim YS, Barkley R, Brechbiel MW. Targeted \u03b1-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody. Panitumumab Translational oncology. 2017;10:535\u201345.","journal-title":"Panitumumab Translational oncology"},{"key":"2636_CR32","first-page":"1881","volume":"40","author":"Z Tan","year":"2012","unstructured":"Tan Z, Chen P, Schneider N, Glover S, Cui L, Torgue J, et al. Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. Int J Oncol. 2012;40:1881\u20138.","journal-title":"Int J Oncol"},{"key":"2636_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2017.04.005","volume":"51","author":"S Westr\u00f8m","year":"2017","unstructured":"Westr\u00f8m S, Generalov R, B\u00f8nsdorff TB, Larsen RH. Preparation of (212)Pb-labeled monoclonal antibody using a novel (224)Ra-based generator solution. Nucl Med Biol. 2017;51:1\u20139.","journal-title":"Nucl Med Biol"},{"key":"2636_CR34","doi-asserted-by":"crossref","unstructured":"Kokov KV, Egorova BV, German MN, Klabukov ID, Krasheninnikov ME, Larkin-Kondrov AA, et al. (212)Pb: Production approaches and targeted therapy applications. Pharmaceutics.\u00a02022;14:189.","DOI":"10.3390\/pharmaceutics14010189"},{"key":"2636_CR35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2967\/jnumed.122.264009","volume":"64","author":"RG Li","year":"2023","unstructured":"Li RG, Stenberg VY, Larsen RH. A novel experimental generator for production of high purity lead-212 for use in radiopharmaceuticals. J Nucl Med. 2023;64:173\u20136.","journal-title":"J Nucl Med."},{"key":"2636_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s41181-021-00121-4","volume":"6","author":"BL McNeil","year":"2021","unstructured":"McNeil BL, Robertson AKH, Fu W, Yang H, Hoehr C, Ramogida CF, et al. Production, purification, and radiolabeling of the (203)Pb\/(212)Pb theranostic pair. EJNMMI radiopharmacy and chemistry. 2021;6:6.","journal-title":"EJNMMI radiopharmacy and chemistry"},{"key":"2636_CR37","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1021\/acs.molpharmaceut.9b00025","volume":"16","author":"J Yang","year":"2019","unstructured":"Yang J, Xu J, Cheuy L, Gonzalez R, Fisher DR, Miao Y. Evaluation of a Novel Pb-203-Labeled Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide for Melanoma Targeting. Mol Pharm. 2019;16:1694\u2013702.","journal-title":"Mol Pharm"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02636-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-023-02636-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02636-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:25:06Z","timestamp":1679862306000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-023-02636-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2636"],"URL":"https:\/\/doi.org\/10.1186\/s13046-023-02636-x","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"29 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal studies were approved by the University of Virginia Institutional Animal Care and Use Committee and performed in compliance with guidelines from the Public Health Service Policy and Animal Welfare Act of the United States.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YSu is an inventor of intellectual properties around the CD46 epitope, the CD46 targeting human antibody, and therapeutic targeting of CD46, which were licensed to Fortis Therapeutics, Inc.SB is an inventor of intellectual properties around the CD46 epitope, the CD46 targeting human antibody, and therapeutic targeting of CD46, which were licensed to Fortis Therapeutics, Inc.YSeo holds equity of Molecular Imaging and Therapeutics, Inc., which were converted to equity of Fortis Therapeutics that licensed intellectual properties from the University of California.RRF reports prior grant funding from Fukushima SiC, outside the existing work.RD received honoraria for consulting from Astellas, Astra Zeneca, Aveo,\u00a0Bayer, BMS, Exelixis, EMD Serono,\u00a0Gilead, Hengrui, Hinova, Janssen, Merck, Myovant, Pfizer, Propella, Sanofi Genzyme, Seattle Genetics, Tavanta, outside of the submitted work.BL is a founder, board member and equity holder of Fortis Therapeutics, Inc., which licensed intellectual properties from the University of California and is conducting clinical trials on CD46 targeting agents. BL also holds equity of Molecular Imaging and Therapeutics, Inc., which were converted to equity of Fortis Therapeutics. BL is an inventor of intellectual properties around the CD46 epitope, the CD46 targeting human antibody, and therapeutic targeting of CD46.JH holds equity of Molecular Imaging and Therapeutics, Inc., which were converted to equity of Fortis Therapeutics that licensed intellectual properties from the University of California.The other authors declare no potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}